EXTON, Pa., Nov. 6, 2013 /PRNewswire/ -- ViroPharma Incorporated (NASDAQ: VPHM) today announced it will present data relating to the quality of life in patients with Hereditary Angioedema (HAE) receiving nanofiltered C1 Inhibitor (C1 INH-nf) replacement therapy for prophylaxis as well as data relating to the Angioedema Clinical Epidemiology Testing Initiative for the study of Hereditary Angioedema (ACET) at the 70th American College of Allergy, Asthma and Immunology (ACAAI) Annual Scientific Meeting. The meeting will take place at the Baltimore Convention Center and the Hilton Baltimore Hotel in Baltimore, Md., Nov. 7-11, 2013. Saturday, November 9 and Sunday, November 10: Embargo lifts November 8 at 12:01 am ESTPoster Presentation Poster ID: P289 Presenter: William Lumry, MD, FAAAI, FACAAI, Medical Director of Asthma and Allergy Research Associates in Dallas, TX Title: "Quality of Life in Patients with Hereditary Angioedema Receiving Nanofiltered C1 Inhibitor for Prophylaxis: Results of a Randomized, Placebo-Controlled, Crossover Study" Authors Present: Saturday, November 9: 12:30 – 1:30 p.m. EST; and Sunday, November 10: 12:00 – 1:00 p.m. EST Location: Halls E & F, Baltimore Convention Center Monday, November 11: Podium Presentation Presenter: Marc Riedl, MD, MS, Associate Professor of Medicine, Director of Clinical Trials, Food, and Drug Allergy Care Center, Section Head, Clinical Immunology and Allergy, UCLA David Geffen School of Medicine in Los Angeles, CA Title: "Prevalence of Diagnosed and Undiagnosed Hereditary Angioedema (HAE) in First-Degree Blood Relatives of Known Subjects with Hereditary Angioedema" Time: 1:00 p.m. – 1:15 p.m. EST Location: Rooms 316-317, Baltimore Convention Center Monday, November 11: Podium Presentation Presenter: H. Henry Li, MD, PhD of the Institute for Asthma and Allergy in Wheaton, MD Title: "Comparison of Chromogenic and Enzyme-Linked Immunosorbent Assay (ELISA) Testing Methods of Functional C1 Inhibitor (C1 INH) in Diagnosing Hereditary Angioedema (HAE)" Time: 1:30 p.m. – 1:45 p.m. EST Location: Rooms 316-317, Baltimore Convention Center About Cinryze ® (C1 esterase inhibitor [human])Cinryze is a highly purified, pasteurized and nanofiltered plasma-derived C1 esterase inhibitor product. In the U.S. and Canada, Cinryze is approved for routine prophylaxis (prevention) against angioedema attacks in adolescent and adult patients with HAE. In the EU, the product is approved for the treatment and pre-procedure prevention of angioedema attacks in adults and adolescents with hereditary angioedema (HAE), and routine prevention of angioedema attacks in adults and adolescents with severe and recurrent attacks of hereditary angioedema (HAE), who are intolerant to or insufficiently protected by oral prevention treatments or patients who are inadequately managed with repeated acute treatment. Cinryze is for intravenous use only. Severe hypersensitivity reactions to Cinryze may occur. Thrombotic events have occurred in patients receiving Cinryze, and in patients receiving off-label high dose C1 inhibitor therapy. Monitor patients with known risk factors for thrombotic events. With any blood or plasma derived product, there may be a risk of transmission of infectious agents, e.g. viruses and, theoretically, the CJD agent. The risk has been reduced by screening donors for prior exposure to certain virus infections and by manufacturing steps to reduce the risk of viral transmission including pasteurization and nanofiltration.
Irish pharmaceuticals company Shire said on Friday it had arranged to hand its Dermagraft skin substitute to Organogenesis and take a $650 million loss on the disposal, which unwinds a major part of an acquisition it made less than three years ago.